Compare Gilead Sciences, Inc. (GILD) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vertiv Holdings Co — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while Vertiv Holdings Co trades at $292.27 (market cap $116.99B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | VRT | |
|---|---|---|
Market Cap | $163.51B | $116.99B |
Sector | Health | Technology |
52-Week High | $155.80 | $376.23 |
52-Week Low | $108.22 | $121.82 |
Enterprise Value | $178.05B | $117.75B |
Dividend Yield | 2.49% | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Vertiv Holdings Co. (VRT) trades at $289.06, down 4.78% over the past 24 hours, with technical indicators signaling a bearish short-term trend. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.17 surpassing the $1.00 estimate. Revenue reached $10.23 billion in 2025, with net income of $1.33 billion, while analyst consensus remains overwhelmingly bullish with a $404.33 price target. Recent news highlights Vertiv's exposure to AI data center infrastructure growth, including a $15 billion order backlog.
The outlook for VRT is positive due to robust AI-driven demand for data center power and cooling solutions, supported by a high analyst buy rating of 94.74%. Key risks include elevated valuation multiples (P/E of 76.53) and competitive pressures in the infrastructure sector. Investors should monitor execution on the large backlog and Q2 2026 earnings release on July 29, 2026, for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
